Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:35:15.995Z.
Calculation as of: 2026-10-06T13:35:15.995Z.
Quote observation: 2026-10-06T13:34:50.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d81df243028a463df18dadfb6b81954a95dec5b5738e9798e17a16434fd93e0
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Acumen Pharmaceuticals, Inc.
Market Cap
$154.28M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.30M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$154.46M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$158.11M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$143.81M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $154.28M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $154.72M | N/A | 109.43 | 140.00 | 140.00 |
| Anavex Life Sciences Corp. (AVXL)vs › | $154.30M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $154.46M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $150.05M | N/A | 32.64 | 32.64 | 32.64 |
| ALX Oncology Holdings Inc. (ALXO)vs › | $158.11M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $160.82M | N/A | 113.17 | 139.63 | 64.33 |
| Immuneering Corporation (IMRX)vs › | $147.02M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $143.81M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.41M | 1.13 | 4.90 | 4.90 | 4.90 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
